ABL

Rockville, United States Founded: 1961 • Age: 65 yrs Acquired By Oxford BioMedica
Contract research and manufacturing for biologics and vaccines are provided.

About ABL

ABL is a Healthcare company based in Rockville (United States) founded in 1961, and was acquired by Oxford BioMedica in September 2023. Contract research and manufacturing for biologics and vaccines are provided. It operates on a Professional Services and Direct-to-Consumer (D2C) model. The company has 15 employees. Its Indian entity Abl Biosciences Private Limited reported revenue of ₹9.39 Cr. ABL offers products and services including Biomanufacturing, ELISA Kits, and Virus Manufacturing. Its focus areas include Biotechnology and Biomanufacturing. Its competitors include KBI Biopharma, Aldevron and Omnia Biologics; 2 of its 3 listed competitors have raised funding.

Company details

ABL, Inc. is involved in the development and manufacturing of vaccines and biotherapeutics. Services are provided in biomanufacturing, virus production, process development, and aseptic fill-finish. Solutions are offered for gene therapies, oncolytic vectors, immunotherapies, and viral vaccines. The company operates in the biotechnology sector, supporting preclinical and clinical development stages. Testing capabilities are also extended through biologics and quality control services. Partnerships with government entities are maintained to advance therapeutic solutions.

  • Headquarters Rockville, United States
  • Employees 15
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website ablinc.com
  • Social LinkedIn Facebook
  • Acquired by BioQual (Feb 2014)
  • Legal Name Abl, Inc.
  • Date of Incorporation 23 Aug, 2012
  • Jurisdiction Hyderabad, Telangana, India
Key Metrics
  • Indian entity revenue
    ₹9.39 Cr

    FY 2025 · -26% YoY

  • Indian entity net profit
    ₹1.55 Cr

    FY 2025 · 16% margin

  • Indian entity EBITDA
    ₹3.47 Cr

    FY 2025 · 37% margin

  • Investors
    OXB

    & 1 more

  • Employee Count
    15
  • Acquired by
    Oxford BioMedica

    & 1 more

    (Sep 2023)

Products & Services of ABL

ABL offers a comprehensive portfolio of products and services, including Biomanufacturing, ELISA Kits, and Virus Manufacturing.

Biomanufacturing
Biotechnology Services

Biomanufacturing services are provided for vaccine development.

ELISA Kits
Biotechnology Products

ELISA kits are offered for research purposes.

Virus Manufacturing
Biotechnology Services

Virus manufacturing is conducted for therapeutic applications.

Investors in ABL

ABL has secured backing from 2 investors. Prominent investors backing the company include OXB and BioQual.

All
InvestorDescriptionFounded YearDomainLocation
Contract research on infectious disease models is conducted.
1981bioqual.comRockville, United States
Gene therapies for multiple diseases are developed via lentiviral systems.
1995oxb.comOxford, United Kingdom
Premium access

Investor details for ABL

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Abl Biosciences Private Limited (ABL)

Abl Biosciences Private Limited is the primary company behind ABL. The board of Abl Biosciences Private Limited currently have 2 directors; the longest-serving is Veeraiah Edara, appointed in 2012.

DirectorDesignationAppointedTenureEntity
Veeraiah Edara
DIN 01920686
Director23 Aug 201214 yrs 2 moAbl Biosciences Private Limited
Venkata Prasanna Lakshmi Edara
DIN 03608984
Director23 Aug 201214 yrs 2 moAbl Biosciences Private Limited

People of ABL

28 people are tracked at ABL (9 in leadership, 19 in team); the tracked headcount is 15.

NameRoleGroup
Yulia Lebedeva
Human Resources DirectorLeadership
Timothy Fouts
VP, Innovation & TranslationLeadership
N-Neka Smith
VP, Quality OperationsLeadership
Stéphanie Colloud
GM & COO, ABL EuropeLeadership
Thierry Van Nieuwenhove
CEOLeadership
Yulia Sayegh
Director of Human ResourcesLeadership
Isabelle Pelletier
Head Of Upstream Process DevelopmentLeadership
Thomas Montague
Director Of Quality AssuranceLeadership
Wah Cheung
Director Of Quality AssuranceLeadership
Roshan B.
Manager, Fill FinishTeam
Yansong Ni
Staff ScientistTeam
Rose Marcheso-Hansen
Manager, Regional SalesTeam
Kathleen Reed
Senior Research SpecialistTeam
Poorni Adikaram
Staff ScientistTeam
Katelyn Sibiski
Quality Assurance ManagerTeam
Michael Roylance
QA Validations ManagerTeam
Carey O'Reilly
QA Specialist IITeam
Shao Deng
Accounting ManagerTeam
Kathleen Drachbar
Quality Assurance Manager - Goverment Services And Supplier QualityTeam
Thanhdao Nguyen
Senior ScientistTeam

8 more people are available in the full profile.

Premium access

Complete people profiles for ABL

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of ABL

Figures of Abl Biosciences Private Limited, the primary company behind ABL, for FY 2025. Revenue was ₹9.39 Cr (-26% year on year). Net profit was ₹1.55 Cr (16% margin). EBITDA was ₹3.47 Cr (37% margin). Revenue has grown at a compounded annual rate of 0% over three years and +20% over five years.

  • ₹9.39 CrRevenue · FY 2025 · -26% YoY
  • ₹1.55 CrNet profit · 16% margin
  • ₹3.47 CrEBITDA · 37% margin
  • ₹2.25 CrPaid-up capital
  • 15Employees (provident fund records)
  • 0%Revenue CAGR, 3 years
  • +20%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Abl Biosciences Private Limited are on its company page.

Premium access

Detailed financial statements for ABL

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of ABL

3 dated milestones of ABL across 62 years, from founding to its latest funding, stage changes and deals.

  1. Founded ABL is founded.
  2. Exit Acquired by BioQual.
  3. Exit Acquired by Oxford BioMedica.

Competitors of ABL

ABL has 3 listed competitors in our database, 2 of them funded. They include KBI Biopharma, Aldevron and Omnia Biologics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
kbibiopharma.com1996Durham, United States$17M1,243
Provider of protein formulation, process & cell line development, and cGMP services
aldevron.com1998Fargo, United States747
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
omniabio.com2001Rockville, United States$25.4M
Process development and manufacturing services for biologics are provided.
Premium access

Detailed competitors of ABL

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of ABL

The website of ABL (ablinc.com) receives about 9.7K visits a month and ranks #3,625,337 among all websites worldwide, #4,667 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    9.7K

    ▲ 87.7% vs previous month

  • Unique visitors
    2.1K

    per month

  • Global rank
    #3,625,337

    among all websites

  • Category rank
    #4,667

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with ABL. Affinity shows how closely the audiences match.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as ABL (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Abl

Premium access

Complete news archive for ABL

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ABL

ABL was founded in 1961.

ABL is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

ABL has 15 employees.

The primary company behind ABL, Abl Biosciences Private Limited, reported revenue of ₹9.39 Cr for FY 2025, down 26% year on year.

ABL, Inc. is involved in the development and manufacturing of vaccines and biotherapeutics. Services are provided in biomanufacturing, virus production, process development, and aseptic fill-finish. Solutions are offered for gene therapies, oncolytic vectors, immunotherapies, and viral vaccines. The company operates in the biotechnology sector, supporting preclinical and clinical development stages. Testing capabilities are also extended through biologics and quality control services. Partnerships with government entities are maintained to advance therapeutic solutions.

ABL's top competitors include KBI Biopharma, Aldevron and Omnia Biologics.

ABL offers Biomanufacturing, ELISA Kits, and Virus Manufacturing.

ABL has 2 investors. Key investors include OXB, and BioQual.

ABL operates through Abl Biosciences Private Limited.

Yes. ABL was acquired by BioQual in February 2014.

The legal entities of ABL currently have 2 directors, including Veeraiah Edara, Venkata Prasanna Lakshmi Edara.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available